Related Experiment Video
Updated: May 29, 2026
Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
Published on: October 26, 2018
Construction of targeted and armed oncolytic adenoviruses
Konstantin Doronin1, Dmitry M Shayakhmetov
1Division of Medical Genetics, University of Washington, Seattle, WA, USA. doronin@uw.edu
Abstract:
Oncolytic (replication-competent) adenoviruses (Ads) represent the most advanced platform for cancer gene therapy. These viral vectors ablate tumors by killing tumor cells in the process of virus replication. As progeny virions are released, they infect remaining cancer cells, generating a bystander effect. Ads engineered for increased cancer specificity produce less damage to normal tissues. First-generation oncolytic Ads have demonstrated acceptable levels of safety while the efficacy was observed only in combination with chemotherapy and/or radiation. Second-generation oncolytic Ads are armed with therapeutic transgenes to increase release, spread, and bystander effect for enhancing the efficacy. Third-generation oncolytic Ads are armed vectors with capsid modifications for transductional detargeting from normal tissues and targeting to cancer cells. Chemical modification of the capsid additionally improves therapeutic window. Here, we describe methods for generation and characterization of advanced-generation oncolytic Ads.
Insights
Advanced oncolytic adenoviruses (Ads) are a promising cancer gene therapy. This study details methods for generating and characterizing next-generation Ads engineered for enhanced tumor targeting and reduced normal tissue damage.
Area of Science:
- Oncolytic virotherapy
- Cancer gene therapy
- Viral vector engineering
Background:
- Oncolytic adenoviruses (Ads) are advanced cancer gene therapy vectors that selectively kill tumor cells.
- Early Ads showed safety but limited efficacy, often requiring combination therapy.
- Next-generation Ads aim to improve tumor specificity, spread, and therapeutic effect.
Purpose of the Study:
- To describe methods for generating advanced-generation oncolytic adenoviruses.
- To detail characterization techniques for these engineered viral vectors.
- To advance the development of more effective cancer treatments.
Main Methods:
- Engineering of replication-competent adenoviruses for enhanced cancer specificity.
- Arming viral vectors with therapeutic transgenes for improved efficacy.
- Modifying viral capsids for targeted delivery and reduced off-target effects.
Main Results:
- Development of third-generation oncolytic Ads with capsid modifications.
- Chemical modifications to improve the therapeutic window.
- Methods for comprehensive characterization of these advanced vectors.
Conclusions:
- Advanced-generation oncolytic Ads offer improved cancer targeting and safety profiles.
- Engineering strategies focus on enhancing viral spread and bystander effects.
- These methods pave the way for more effective oncolytic virotherapy strategies.